A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2023
This article has no abstract
Epistemonikos ID: 5a1c31cbdbd6596dd1002b1a90d38beb7bfb0021
First added on: Apr 11, 2025